Ablynx

@AblynxABLX

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies® for a range of serious human diseases.

Ghent/Zwijnaarde, Belgium
ablynx.com
Регистриран през май 2012 г.
5 Снимки и видеоклипове Снимки и видеоклипове

Туитове

Блокираш @AblynxABLX

Наистина ли искаш да видиш тези туитове? Това няма да разблокира @AblynxABLX

  1. ретуитна
    26.07

    FDA designates top nanobody caplacizumab fast track designation: 6-10 months faster approval

    3 ретуита 4 харесва
  2. ретуитна
    20.07

    2.4bn "bioeuro": Belgian Nanobody delights now also tasteful in France

    2 ретуита 7 харесва
  3. 20.07

    and Sanofi to develop up to 8 Nanobody®-based therapeutics focused on immuno-inflammatory diseases

    1 reply 9 ретуита 14 харесва
  4. 27.06

    achieves second milestone in immuno-oncology collaboration with Merck & Co., Inc.

    7 ретуита 16 харесва
  5. 26.06

    initiates a single and multiple dose Phase I study of caplacizumab in healthy Japanese subjects

    4 ретуита 6 харесва
  6. 29.05

    launches , a new website dedicated to Thrombotic Thrombocytopenic Purpura (TTP)

    10 ретуита 9 харесва
  7. 22.05

    receives €15M milestone from Merck KGaA for novel Nanobody in osteoarthritis

    10 ретуита 12 харесва
  8. 18.05

    Meet our experts and recruiters (booth 99) @

    2 харесва
  9. 11.05

    Ablynx zit op schema via

    4 ретуита 6 харесва
  10. 11.05

    Q1 2017 "Positive start of the year; good progress in multiple programmes; strong cash position"

    6 ретуита 4 харесва
  11. 10.05

    Publication in Journal of Thrombosis and Haemostasis "Caplacizumab reduces major thromboembolic events"

    7 ретуита 7 харесва
  12. 2.05

    successfully completes patient recruitment in its Phase III Hercules study of caplacizumab

    2 ретуита 6 харесва
  13. 7.04

    Annual Report 2016 is available online - view via

    1 ретуит 4 харесва
  14. 7.04

    - Adrianus van Herk (aandeelhouder Ablynx): 'België en Nederland zijn wereldtop' via @trends

    1 ретуит 4 харесва
  15. ретуитна
    6.03

    Compelling data for developed psoriasis nanobody in collaboration

    3 ретуита 2 харесва
  16. ретуитна
    28.02

    Good morning to those waking up in Europe, Africa and the Middle East! Share with us what you have planned for today!

    15 replies 51 ретуита 103 харесва
  17. ретуитна
    24.02

    you will find out that is dedicated to creating new medicines which will make a real difference to society!

    1 ретуит 1 харесват
  18. 23.02

    FYR 2016: significant progress in R&D pipeline; strong cash position; major catalysts in 2017.

    4 ретуита 3 харесва
  19. 9.02

    will present additional data from the Phase IIb RA combination study of vobarilizumab at the Annual CRA Meeting

    2 ретуита 2 харесва
  20. 6.02

    Ablynx files caplacizumab for ultra rare blood disorder
    6 ретуита 9 харесва

Потребителят @AblynxABLX още не е туитвал.

Изглежда зареждането отнема известно време.

Twitter може да е претоварен или да изпитва моментно затруднение. Опитай отново или виж Twitter Status за повече информация.

    Може също да харесаш

    ·